Tuesday, November 29, 2011

Green Baron 102^nd New “Stock Pick”

Amarantus BioSciences, Inc.

(OTCBB: AMBS – $.17 per share)

www.amarantus.com  

New Video Stock Chart Now Available on our home page:

www.TheGreenBaron.com

New Interview with CEO Gerald Commissiong at: www.thegreenbaron.com/Webcasts.htm

Amarantus BioSciences Targets $3 Billion Global Market using its Patented and Proprietary MANF Platform to Treat Parkinson’s Disease

Pre-clinical Experiment Funded from the Michael J. Fox Foundation for Parkinson’s Research Confirms Potential for Benefits

Recent News: Amarantus BioSciences and Banyan Biomarkers announce Traumatic Brain Injury Research Collaboration

The Green Baron believes AMBS will be the next major winner from the biotech sector; This low priced stock could certainly trade in the dollars!

After last week’s announcement that Gilead Sciences (GILD) will acquire Pharmasset (VRUS) in an all cash $11 billion takeover, investors are searching for other biotech stocks that could be next.  Cash from the huge transaction is likely to find a home in a slew of up and coming biotech stocks.  "These deals tend to happen in waves," says Dan Veru, Palisade Capital Management's chief investment officer.

Although most of the money expected to chase biotech stocks in the coming weeks will go into more established names, The Green Baron Report believes it has identified the next major winner in the biotech sector among low-priced stocks, and we anticipate it will soon gain serious attention from investors:

The Green Baron Report officially selects Amarantus BioSciences, Inc. (OTCBB: AMBS) as our 102nd Green Baron “Stock Pick” since inception.  Results compiled from the most recent trade prior to dissemination of this report to the subsequent high will be closely monitored at www.thegreenbaron.com and through email updates to members.  We have very aggressive price projections for AMBS and believe the stock has huge upside potential based on several positive fundamental and technical factors.

TRADER’S NOTES:   AMBS is a fully reporting OTC Bulletin Board listed stock.  Active trading took place in AMBS shortly after it began to trade publicly in late July / early August at prices between .23 and .48 per share.  After hitting about .40 in mid-August, AMBS pulled back to trade in a range from mid-August through the end of October primarily between .10 and .20 per share.

The current shareholder base appears to be extremely supportive and a tightly held bunch.  AMBS has the ability to rally a huge amount on relatively low volume as evidenced on November 1 when The Green Baron Report issued a “Trading Alert” on AMBS.  That day, AMBS hit a high of .50 per share up as much as 163.15% from our profile price of .19 per share.  

We believe the pullback and consolidation over the past three weeks represents another fantastic opportunity to accumulate AMBS at low prices ahead of the next big move.  There appears to be solid support at .12 per share with little overhead resistance. 

Parkinson’s disease affects more than a million people in the United States alone and remains a disease with no cure.  Amarantus BioSciences has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson’s disease and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF").

Although Amarantus was founded in January 2008, it acquired the data and assets from its predecessor from Canada.  The previous Company successfully raised over $12 million, and although that Company took a wrong path, previous successes and errors provide extremely valuable information for AMBS going forward. 

The Green Baron Report has selected several primary reasons why our members and other investors should seriously consider accumulating AMBS common stock now:

·         Proprietary and Patented Intellectual Property Covering Wide Array of Therapeutic Applications – Last month Amarantus received a Notice of Allowance from the United States Patent & Trademark Office ("USPTO"). The patent application claims include the discovery of mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of a range of apoptosis-related diseases including Parkinson's disease. This new patent complements Amarantus' existing collection of issued patents throughout Europe and pending patent applications worldwide on its proprietary MANF platform.

·         PhenoGuard Cell Lines – Amarantus will continue to file patents and build a strong intellectual property portfolio from their inventory of 88 cell lines referred to as “PhenoGuard Cell Lines”.  MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line, but the possibilities are limitless. These therapeutic proteins aim to address a host of major apoptosis-related diseases including Alzheimer’s disease, epilepsy, macular degeneration and traumatic brain injury.

·         Potential New Funding from The Michael J. Fox Foundation for Parkinson’s Research – Amarantus could make headlines should it continue to forge ahead with positive progress for a therapy or treatment for Parkinson’s disease.  Management maintains a positive relationship with the foundation, and a new funding arrangement would likely have very positive implications to the stock price of AMBS.

·         New Research Collaboration Announced Last Week – Amarantus and Banyan Biomarkers announced a collaboration agreement to evaluate MANF’s potential as a disease-modifying agent for the treatment of Traumatic Brain Injury, commonly known as concussions.  The goal is to pair the potential therapeutic treatments such as MANF alongside Banyan’s groundbreaking diagnostic test. 

·         Solid Leadership – The Management Team includes Chief Scientific Officer Dr. John Commissiong who discovered MANF in 2003.  The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology.  Dr. Commissiong believes that a fundamental understanding of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-related disorders.  President & CEO Gerald Commissiong is a Stanford graduate that went on to play professional football in Canada.  CFO Marc Faerber has over thirty years of experience and over nineteen of those in life sciences. His experience has spanned Fortune 500 companies to start-ups, and everything in between.

·         Dr. Owen Garrick Joins as Strategic Advisor – Clearly if you read more about Dr. Garrick you will understand his potential positive influence.  Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the President of the American Medical Association Foundation. Dr. Garrick previously held positions as Director of Corporate Strategy at McKesson Corporation, Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals and received his MD from Yale School of Medicine.

·         Valuation and Technicals – The market cap for AMBS is now less than $10 million, a mere speck of the potential value that the stock would command if progress continues to be positive.  At each milestone that is successfully met, AMBS would gain significant attention from other industry players.  AMBS stock is currently sitting on good technical support.

Green Baron Analysis:

Amarantus BioSciences is structured for success.  The Company has acquired and will build its intellectual property portfolio.  MANF represents a potential treatment for a range of diseases including Parkinson’s, and the Company last month received its Notice of Allowance from the United States Patent & Trademark Office.  This was a significant development that alone could be worth far more than today’s trading value in the stock.

The management team, the advisory team and its strategic advisors are as experienced as any small biotech company we have seen.  The involvement of several members is a strong testament to this Company without even looking further.  We urge members and investors to visit the Company’s website or read the end of this report to view the resumes and background of this veteran team.

Biotechnology stocks can be challenging to value because it takes so long be granted FDA approval and begin to produce revenue.  The valuation comes from positive milestones that are successfully met, and the potential markets for the treatments that are being developed.  The Company already has years of data and development of MANF under its belt, and its Chief Science Officer and Founder Dr. John Commissiong is clear on where to take this next. 

The Green Baron Report is confident that Amarantus is gaining respect in the biotech community.  We view the stock as a bargain at its current valuation, and we believe AMBS should command a $50 to $100 million valuation when granted approval to begin human clinical trials.  Due to the fact that there is currently no cure for Parkinson’s, any treatment demonstrating efficacy and safety could get fast tracked through the FDA testing and clearance process. 

The sky is the limit for AMBS, but a $50 to $100 million valuation would put AMBS at a price of .74 to $1.49 per share at the current share count.  Therefore, we believe our members would be wise to accumulate at or near our current profile price.